Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

TECXAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ721.81+ 1.35%S&P 500 · SPY770.08+ 0.62%Dow Jones · DIA523.40+ 0.08%Russell 2000 · IWM280.14+ 1.14%

Tectonic Therapeutic, Inc. (TECX) Presents at CureHHT 16thHHT International Scientific Conference - Slideshow
2026-10-14. The following slide deck was published by Tectonic Therapeutic, Inc.
SeekingAlpha15:0213 Days AgoTECX

05:00Oct 121 Story

UBS Initiates Coverage On Tectonic Therapeutic with Neutral Rating, Announces Price Target of $26
UBS analyst Alice Nettleton initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Neutral rating and announces Price Target of $26.
Benzinga05:40TECX

08:00Sep 291 Story

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S.TX2100 Phase 1a clinical trial topline results demonstrated single ascending doses of TX2100 were generally safe and well-tolerated in healthy adult volunteersCompany plans to initiate an open-label TX2100 Phase 1b clinical trial in patients with hematologic-support dependent HHT by year-end 2026, and initiate a
Yahoo08:00TECX

00:00Sep 101 Story

Tectonic Therapeutic (TECX) Clears Two Trial Hurdles With Cash To Spare
On August 6, Tectonic Therapeutic (NASDAQ:TECX) reported second quarter results built around two clinical wins rather than sales figures, since this is a clinical stage biotech company with no products on the market yet. The headline news is that both of its lead programs hit their scheduled marks this year, and the company says it […]
Yahoo00:55TECX

05:00-14:00Aug 72 Stories

HQH: After Biotech's Breakout Year, This Healthcare CEF Still Trades Below NAV; Buy
Abrdn Healthcare Investors biotech CEF: 6.4% NAV discount, 56% NAV gain, 12% gain-funded payout, key risks. Read my analysis here on HQH.
SeekingAlpha13:58
Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $93
Wells Fargo analyst Tiago Fauth maintains Tectonic Therapeutic (NASDAQ:TECX) with a Overweight and lowers the price target from $101 to $93.
Benzinga05:58TECX

13:00Aug 61 Story

Tectonic Therapeutic Q2 EPS $(1.18) Beats $(1.37) Estimate
Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.18) per share which beat the analyst consensus estimate of $(1.37) by 13.87 percent. This is a 10.28 percent decrease over losses of $(1.07) per share
Benzinga13:44TECX